Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

Neurology Today in 5

American Academy of Neurology

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

APR 18, 20244 MIN
Neurology Today in 5

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

APR 18, 20244 MIN

Description

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.